Amoxicillin News
Most Popular Amoxicillin Story
ALSO NOTED: Elan, Biogen submit Tysabri for Crohn's; Affymax prices IPO;and much more...
> Shares of Elan and Biogen Idec were on the rise this morning after the two developers announced that they had submitted Tysabri as a therapy for Crohn's disease. Report
> Affymax priced its IPO of 3.7 million shares at $25 a share. Release
> Advancis Pharmaceutical …
... Read more...Latest Headlines
- January 24, 2008
- September 12, 2006
- August 10, 2006
- July 28, 2005
- July 25, 2005
- July 21, 2005
- June 15, 2005
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
